1-6 of 6
Glen Justice, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Julie M. Vose, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Izidore S. Lossos, MD, Annette Ervin-Haynes, DO, Kenichi Takeshita, MD, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD
Journal: Blood
Blood (2007) 110 (11): 2570.
https://doi.org/10.1182/blood.V110.11.2570.2570
Published: 2007
Journal Articles

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Timothy D. Moore, MD, Craig B. Reeder, MD, Craig E. Cole, MD, Glen Justice, MD, Henry P. Kaplan, MD, Michael Voralia, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD
Journal: Blood
Blood (2007) 110 (11): 2560.
https://doi.org/10.1182/blood.V110.11.2560.2560
Published: 2007
Journal Articles

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

Joseph M. Tuscano, MD, Izidore S. Lossos, MD, Glen Justice, MD, Julie M. Vose, MD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD
Journal: Blood
Blood (2007) 110 (11): 2563.
https://doi.org/10.1182/blood.V110.11.2563.2563
Published: 2007
Journal Articles

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Izidore S. Lossos, MD, Peter H. Wiernik, MD, Glen Justice, MD, Joseph M. Tuscano, MD, Craig E. Cole, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD
Journal: Blood
Blood (2007) 110 (11): 2564.
https://doi.org/10.1182/blood.V110.11.2564.2564
Published: 2007
Journal Articles

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Peter H. Wiernik, MD, Izidore S. Lossos, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Craig E. Cole, MD, Kyle McBride, MS, Kenton Wride, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD
Journal: Blood
Blood (2007) 110 (11): 2565.
https://doi.org/10.1182/blood.V110.11.2565.2565
Published: 2007
Journal Articles

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Peter H. Wiernik, MD, Izidore Lossos, MD, Joseph Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD,PhD, Thomas M. Habermann, MD
Journal: Blood
Blood (2006) 108 (11): 531.
https://doi.org/10.1182/blood.V108.11.531.531
Published: 2006